Aims To determine the effects of digoxin on all-cause mortality and heart failure (HF)
hospitalizations, regardless of ejection fraction, accounting for serum digoxin concentration …

BACKGROUND: In heart failure (HF), digoxin at low serum digoxin concentrations (SDC)
reduces all-cause mortality and HF hospitalizations. However, the effects of digoxin on other …

Aims In the Digitalis Investigation Group (DIG) trial, digoxin reduced mortality or
hospitalization due to heart failure (HF) in several pre‐specified high‐risk subgroups of HF …

Context The Digitalis Investigation Group (DIG) trial reported that digoxin provided no overall
mortality benefit and only a modest reduction in hospitalizations among patients with heart …

Objectives: We sought to determine whether there was a relationship between serum
digoxin concentration (SDC), including SDCs typically regarded as low, and clinical efficacy …

Post hoc analyses of the Digitalis Investigation Group (DIG) trial indicate that digoxin at low
(0.5 to 0.9 ng/ml) serum digoxin concentration (SDC) reduces mortality, which is eliminated …

Abstract Aims The Digitalis Investigation Group (DIG) trial, the only large randomized trial of
digoxin in heart failure, reported a neutral effect on mortality and a significant reduction in …

Background The role of cardiac glycosides in treating patients with chronic heart failure and
normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality and …

Background—About half of the 5 million heart failure patients in the United States have
diastolic heart failure (clinical heart failure with normal or near-normal ejection fraction) …

There are conflicting data regarding the effect of digoxin use on mortality in patients with
atrial fibrillation (AF) or with congestive heart failure (CHF). The aim of this meta-analysis …